Valued for their tech, Silicon Valley digital health companies rely heavily on armies of faraway coaches
SAN FRANCISCO — Talk to investors about why they like Omada Health, and they point…
Author: STAT
STAT Plus: More Americans can’t afford prescriptions and most think Trump isn’t doing enough to help
As President Trump looks toward the next election, a new poll finds that a growing…
Former FDA commissioner calls for a full ban on pod-based e-cigarettes
Former Food and Drug Administration Commissioner Scott Gottlieb is done playing nice on e-cigarettes. He’s…
STAT Plus: Pharmalittle: Biotechs worry about Democrats’ drug pricing bill; PhRMA criticizes four countries over policies
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
Meet the 2019 STAT Wunderkinds
Read their stories. Read Original Article: Meet the 2019 STAT Wunderkinds »
Opinion: Should employers take a chance on little-known Embarc to pay for gene therapy?
The promise of curing deadly diseases by administering a one-time therapy that rewrites a patient’s…
It’s tiny biotechs — not big drug makers — that fear ‘nuclear winter’ from Pelosi’s drug pricing bill
WASHINGTON — No one asked Paul Hastings what he thinks about Speaker Nancy Pelosi’s major…
STAT Plus: India’s health care challenges and tech workforce make it fertile ground for AI startups
BENGALURU, India — In September, when Google announced the opening of an artificial intelligence lab…
Google partners with major U.S. health system, gaining access to vast patient data in the process
Google has quietly launched a project with one of the nation’s largest nonprofit health systems…
Cholesterol levels dropping in U.S., but many still need care
WASHINGTON — Some good health news: Americans’ cholesterol levels are dropping, and more people at…
STAT Plus: How much? Pharma copay cards are increasing costs for private Canadian insurers
Amid ongoing criticism of discount cards for prescription medicines, a new study finds these marketing…
Opinion: Confidentiality orders in drug, device lawsuits harm patients and the public
In 2001, West Virginia became the first state to sue Purdue Pharma, the maker of…
Opinion: Diabetic foot ulcers: a silent killer of veterans
Veterans who survive the horrors of war or the other dangers of military service often…
STAT Plus: Long-neglected gene plays a bigger role in Alzheimer’s than suspected, study shows
Just days after news that an ultra-rare form of a cholesterol-related gene called APOE protected…
More than ever before, Democratic presidential hopefuls want to take on pharma. Here’s how they’d do so
The post below is adapted from a STAT Report, “Democrats and drug pricing,” a deeply…
STAT Plus: FDA admits it goofed when granting orphan status to an opioid addiction treatment
In an unusual move, the Food and Drug Administration has acknowledged a mistake and revoked…
STAT Plus: Fibrogen discloses new data that eases heart-safety concerns about experimental anemia pill
Fibrogen presented new clinical trial data on Friday that alleviates concerns about the heart safety…
In a breakthrough, health officials identify possible culprit behind vaping illnesses: vitamin E acetate
Health officials have identified a possible culprit behind the spate of vaping-related illnesses that have…
STAT Plus: Former Biogen sales rep, who says she was fired for complaining about off-label marketing, is awarded $6 million
A federal jury in Seattle has awarded nearly $6 million to a former Biogen (BIIB)…
Top Trump official suggests tobacco regulation distracts from FDA mission
WASHINGTON — President Trump’s domestic policy chief on Friday suggested the regulation of tobacco and…
This booth can virtually connect patients with clinicians and dispense medications. Will patients use it?
TAMPA, Fla. — The bright blue box isn’t big. But squeezed inside it, there’s a…
STAT Plus: A medicinal chemist sees some red flags on China’s newly approved Alzheimer’s drug
Over the weekend, the world got some staggering and perhaps hopeful news. China’s equivalent of…
Sarepta Therapeutics CEO playing nice with FDA over rejection of Duchenne drug
Sarepta Therapeutics CEO Doug Ingram is taking the high road. In remarks Thursday on a…
Listen: An uncertain Alzheimer’s idea, blockbuster fish oil, & a little self-indulgence
Is the latest Alzheimer’s drug for real? Is three a crowd in CAR-T? And what’s…
STAT Plus: Italy is urged not to replace a public health official who pushed for drug pricing transparency
Nearly two dozen health and consumer advocacy groups are urging the Italian health minister not…
STAT Plus: Another former Sun Pharma sales rep claims she was fired for complaining about off-label marketing
A former Sun Pharmaceutical sales employee has a filed a lawsuit claiming retaliation for objecting…
.jpg)
Number of U.S. cases of vaping-related illness tops 2,000
NEW YORK — New government figures show more than 2,000 people have been diagnosed with…
STAT Plus: Startup Arkuda targets rapidly advancing, rare form of dementia
A rare inherited form of early-onset dementia that typically strikes people between the ages of…
STAT Plus: Pharmalittle: HHS sues Gilead over HIV PrEP pill patents; Purdue and Sacklers shielded from lawsuits until April
Top of the morning to you and a fine one it is. Despite gloomy skies…
A Takeda vaccine for dengue appears effective, but the story is nuanced
In the wake of controversy over a Sanofi dengue vaccine, Takeda Pharmaceuticals is betting its…
When it comes to health care, nothing is nonpartisan. Melania Trump’s visit to a Boston hospital harms patients and providers
This morning I was alarmed to learn of first lady Melania Trump’s visit to Boston…
STAT Plus: If Trump were to place tariffs on Swiss drugs, U.S. patients are most likely to get hurt
In the latest bit of saber rattling over trade, the Trump administration last month reportedly…
STAT Plus: Regeneron is buying back $1 billion in stock, but hell has not yet frozen over
A version of this story appeared in STAT’s biotech newsletter, The Readout. Sign up here….
Opinion: Digital endpoints library can aid clinical trials for new medicines
At nearly every major industry conference — from HLTH to CNS Summit, Exponential Medicine, and Rock…
First use of CRISPR against cancer in patients clears early safety hurdles
The first attempt in the United States to use a gene editing tool called CRISPR…
STAT Plus: Pharmalittle: Trump splits from Pelosi to back Senate drug pricing bill; UPS drones make first delivery for CVS
Hello, everyone, and welcome to the middle of the week. You made it this far,…
STAT Plus: What money? The CDC is urged to acknowledge industry funding
Several advocacy groups petitioned the Centers for Disease Control and Prevention to stop making claims…
STAT Plus: China has become the pharmacy to the world — and a national security risk for the U.S.
As concern mounts over the global pharmaceutical supply chain, more fingers are being pointed at…
STAT Plus: Pharmalittle: Canadian ambassador says imports would not lower U.S. prices; can the Sackler legacy be rebuilt?
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT Plus: After an unprecedented death, FDA is offered divergent forecasts on future of fecal transplants
They may be unparalleled lifesavers. Or they may be keeping lifesaving drugs off the market….
Opinion: The emergence of laboratory benefits managers: PBM déjà vu?
Pharmacy benefits managers (PBMs), the companies that administer prescription drug coverage for employers, municipalities, insurance…
From assisted hatching to embryo glue, most IVF ‘add-ons’ rest on shaky science, studies find
By the time Sarah Chamberlin’s fertility doctor declared her genes “incompatible” with her husband’s and said…
STAT Plus: With high stakes, eight experts would wield extraordinary influence on fate of Biogen’s Alzheimer’s drug
After 17 years of hope and frustration, the decision over whether to approve, at last,…
STAT Plus:
About Headed to San Francisco for the 2020 J.P. Morgan Healthcare Conference? Join us…
A new Alzheimer’s therapy is approved in China, delivering a surprise for the field but also questions
Chinese regulators have granted conditional approval to an Alzheimer’s drug that is derived from seaweed,…
STAT Plus: Four state treasurers urge Cardinal Health shareholders to reject a board member
As Cardinal Health grapples with criticism of its role in the opioid crisis, a group…
She was destined to get early Alzheimer’s, but didn’t. Did a rare mutation protect her?
A woman with a genetic mutation thought to inevitably cause Alzheimer’s disease in people’s 50s…
STAT Plus: Pharmalittle: China OKs first home-grown Alzheimer’s drug; White House cool to Pelosi drug pricing bill
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: Cleveland Clinic’s Nissen denies any communication with FDA about Amarin’s Vascepa
Drama, thy name is Amarin. If you want to get a rise out of investors…
STAT Plus: Halozyme’s lead drug fails; company will cut 55% of workforce in bid for profitability
Halozyme, a San Diego-based biotech, said Monday that its lead drug, for pancreatic cancer, had…